About Rubius Therapeutics
Rubius Therapeutics is a company based in Cambridge (United States) founded in 2015.. Rubius Therapeutics has raised $245 million across 4 funding rounds from investors including Flagship Pioneering and SLR Investment Corp. The company has 256 employees as of December 31, 2022. Rubius Therapeutics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter Cambridge, United States
- Employees 256 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Rubius Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$245 M (USD)
in 4 rounds
-
Latest Funding Round
$25 M (USD), Debt – Conventional
Dec 21, 2018
-
Investors
Flagship Pioneering
& 1 more
-
Employee Count
256
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of Rubius Therapeutics
Rubius Therapeutics has successfully raised a total of $245M across 4 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $25 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Debt – Conventional — $25.0M
-
First Round
First Round
(09 Dec 2015)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2018 | Amount | Debt – Conventional - Rubius Therapeutics | Valuation |
investors |
|
| Mar, 2018 | Amount | Series B - Rubius Therapeutics | Valuation |
investors |
|
| Jun, 2017 | Amount | Series B - Rubius Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Rubius Therapeutics
Rubius Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Flagship Pioneering and SLR Investment Corp. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Debt and equity investments are offered by the firm.
|
Founded Year | Domain | Location | |
|
Life sciences-focused venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Rubius Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Rubius Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Rubius Therapeutics Comparisons
Competitors of Rubius Therapeutics
Rubius Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Rubius Therapeutics
Frequently Asked Questions about Rubius Therapeutics
When was Rubius Therapeutics founded?
Rubius Therapeutics was founded in 2015.
Where is Rubius Therapeutics located?
Rubius Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Rubius Therapeutics a funded company?
Rubius Therapeutics is a funded company, having raised a total of $245M across 4 funding rounds to date. The company's 1st funding round was a Series B of $120M, raised on Dec 09, 2015.
How many employees does Rubius Therapeutics have?
As of Dec 31, 2022, the latest employee count at Rubius Therapeutics is 256.
What does Rubius Therapeutics do?
Rubius Therapeutics was founded in 2015 in Cambridge, United States, within the biotechnology sector. The companys operations focus on the Erythrocyte Design platform, where hematopoietic stem cells are genetically altered to produce functionalized red blood cells expressing biotherapeutic proteins. These therapeutics are developed for applications in metabolic deficiencies, autoimmune disorders, and cancer, with over 50 prototypes validated in preclinical models.
Who are the top competitors of Rubius Therapeutics?
Rubius Therapeutics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Who are Rubius Therapeutics's investors?
Rubius Therapeutics has 2 investors. Key investors include Flagship Pioneering, and SLR Investment Corp.